Drug Sponsors

ImmunoGen to cut workforce 17%

Tuesday, October 4, 2016

ImmunoGen, a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, has announced the completion of a strategic review of its operations. As a result of this initiative, the company will reduce its workforce by 17% and seek to partner its non-core B-cell lymphoma programs, creating a stronger organization focused on delivering innovative ADC therapies that meaningfully improve the lives of cancer patients.

[Read More]

Pfizer will not split

Tuesday, September 27, 2016

Pfizer has announced that, after an extensive evaluation, the company’s board of directors and executive leadership team have determined the company is best positioned to maximize future shareholder value creation in its current structure and will not pursue splitting Pfizer Innovative Health and Pfizer Essential Health into two separate, publicly traded companies at this time.

[Read More]

CHOP launches Roberts Collaborative for Genetics and Individualized Medicine

Monday, September 26, 2016

The Children’s Hospital of Philadelphia (CHOP) has announced the creation of the Roberts Collaborative for Genetics and Individualized Medicine at CHOP. The $50 million Roberts Collaborative will position CHOP at the forefront of pediatric genetics research and will take a multidisciplinary approach toward diagnostics, clinical management, consulting, therapeutics and research driven by the power of genetics. The Roberts family is the principal source of external funding for this initiative, with a $25 million gift that will facilitate the integration of all clinical departments, divisions and centers for the care of pediatric patients, as well as advance a relentless pursuit of breakthrough cures for childhood disease.

[Read More]

GE Healthcare launches $50M global health startup accelerator

Monday, September 26, 2016

GE Healthcare, the $18 billion healthcare technology division of GE, launched the company’s first healthcare accelerator, five.eight, aimed at improving healthcare outcomes for the world’s developing economies. The accelerator will target global health startups with a vision to improve healthcare quality and accessibility in developing or low-resource settings—from education and training to disruptive, low-cost technologies and digital applications.

[Read More]

Alnylam opens new European office in Maidenhead, UK

Thursday, September 22, 2016

Alnylam Pharmaceuticals, an RNAi therapeutics company, has announced the expansion of its global footprint with the opening of a new development and commercial hub in Maidenhead, U.K. In anticipation of substantial growth across Alnylam over the next five years, the office opens with a core clinical development, regulatory affairs and commercial team and space for an additional 100 employees.

[Read More]

Allergan to acquire Tobira Therapeutics for $1.7B

Wednesday, September 21, 2016

Allergan, a global pharmaceutical company, and Tobira Therapeutics, a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for non-alcoholic steatohepatitis (NASH) and other liver diseases, have entered into a definitive agreement under which Allergan will acquire Tobira for an upfront payment of $28.35 per share, in cash, and up to $49.84 per share in Contingent Value Rights (CVRs) that may be payable based on the successful completion of certain development, regulatory and commercial milestones, for a total potential consideration of up to $1.695 billion.

[Read More]

Premier Biomedical, ATS form Premier Biomedical Pain Management Solutions

Tuesday, September 20, 2016

Premier Biomedical has announced the signing of an agreement forming a joint venture company with Advanced Technologies Solutions (ATS), a San Diego, California enterprise. The joint venture company, Premier Biomedical Pain Management Solutions, will develop and market natural and cannabis-based generalized, neuropathic, and localized pain relief treatment products. Sales for the initial product, an extended-duration topical patch, are expected in early 2017, with a variety of follow-on opioid-free pain relief products launching soon thereafter. Sample pain management products are being manufactured and will be available in limited quantities beginning next month.

[Read More]

Eisai establishes AiM Institute for precision medicines

Tuesday, September 20, 2016

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., has announced the launch of the Eisai Andover innovative Medicines (AiM) Institute, a discovery innovation unit within the greater Boston biopharma hub. With 90 integrated scientists at a state-of-the-art research facility in Andover, Massachusetts, the Institute is focused on executing novel therapeutic targets validated by human genetics and related data to discover and develop precision medicines for some of the hardest-to-treat medical conditions including dementia, cancer and auto-immune diseases.

[Read More]